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Clopidogrel is an antiplatelet drug widely used in themanagement of coronary artery disease.1 It de-creases the incidence of coronary artery stent throm-
bosis2,3 and has been approved for the management of non-
ST-segment elevation myocardial infarction.4
Recent reports have indicated a lack of platelet inhibitory ac-
tivity by clopidogrel (clopidogrel resistance) in some patients.5–8
The drug interaction of clopidogrel with CYP3A inhibitors has
been suggested as a mechanism of this resistance.9–11
Clopidogrel is a prodrug that needs to be metabolized be-
fore it can inhibit adenosine diphosphate (ADP)-induced
platelet aggregation (Fig. 1). Metabolism is predominantly by
the cytochrome P450 (CYP) 3A system, which consists of the
3A4 and 3A5 isoenzymes.9 CYP3A4 is generally thought to be
the predominant form expressed in liver cells. However,
CYP3A5, which is expressed polymorphically in the liver,12
may contribute as much as 50% to hepatic CYP3A activity in
one-third of white people and in half of black people.13
The CYP3A5 gene has a functional polymorphism that dis-
tinguishes expressor (*1) and non-expressor (*3) alleles.14
This polymorphism has been reported to influence total
CYP3A activity and shows racial differences in its frequency.13
For drugs equally metabolized by CYP3A4 and CYP3A5,
the net rate of metabolism is the sum of CYP3A4 and CYP3A5
metabolism rates.13 Thus, a substantial change in CYP3A5 ac-
tivity may influence the pharmacokinetics of CYP3A sub-
strates, such as midazolam, triazolam, nifedipine,15 tacroli-
mus16 and lipophilic statins17 (Fig. 2).
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Increased risk of atherothrombotic events associated
with cytochrome P450 3A5 polymorphism in patients
taking clopidogrel
Background: Clopidogrel is a prodrug requiring metabolism
by cytochrome P450 3A (CYP3A) isoenzymes, including
CYP3A5, in order to be active. It is controversial whether
clopidogrel interacts with CYP3A inhibitors. We investigated
the influence of CYP3A5 polymorphism on the drug interac-
tion of clopidogrel.
Methods: In phase 1 of the study, we administered clopido-
grel to 16 healthy volunteers who had the CYP3A5 non-
expressor genotype (*3 allele) and 16 who had the CYP3A5
expressor genotype (*1 allele) with and without pretreat-
ment with itraconazole, a potent CYP3A inhibitor. A platelet
aggregation test was performed at baseline, 4 hours, 24
hours and 6 days after clopidogrel administration. In phase
2, we compared clinical outcomes of 348 patients treated
with clopidogrel after successful coronary angioplasty with
bare-metal stent implantation according to their CYP3A5
genotype; the primary end point was a composite of athero-
thrombotic events (cardiovascular death, myocardial infarc-
tion and non-hemorrhagic stroke) within 1 and 6 months af-
ter stent implantation.
Results: In phase 1, the change in platelet aggregation after
clopidogrel administration and pretreatment with itracona-
zole was greater among the subjects with the CYP3A5 ex-
pressor genotype than among those with the non-expressor
genotype: 24.9% (standard deviation [SD] 13.9%) v. 6.2%
(SD 13.5%) at 4 hours (p < 0.001); 27.7% (SD 16.5%) v. 2.5%
(SD 8.3%) at 24 hours (p < 0.001); and 33.5% (SD 18.6%) v.
17.8% (SD 13.8%) at day 7 (p < 0.01). In phase 2, athero-
thrombotic events occurred more frequently within 6
months after stent implantation among the patients with the
non-expressor genotype than among those with the expres-
sor genotype (14/193 v. 3/155; p = 0.023). Multivariable
analysis showed that the CYP3A5 polymorphism was a pre-
dictor of atherothrombotic events in clopidogrel users.
Abstract Interpretation: People with the CYP3A5 non-expressor geno-
type are vulnerable to drug interactions between clopidogrel
and CYP3A inhibitors. This phenomenon may be associated
with worse outcomes in patients with the non-expressor
genotype who are given clopidogrel after coronary angio-
plasty and implantation of bare-metal stents.
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We postulated that the drug interaction between clopi-
dogrel and a CYP3A inhibitor would differ according to a
person’s CYP3A5 genotype. To test this hypothesis, we first
investigated, in volunteers, the association between
CYP3A5 genotype and platelet aggregation after clopido-
grel administration with or without CYP3A inhibition
(phase 1). We then investigated the influence of this geno-
type on risk of atherothrombotic events among patients




The study protocol was approved by the Institutional Review
Board of Seoul National University Hospital (SNUH), and the
study was conducted at the SNUH Clinical Trial Center. All
subjects provided written informed consent before
enrolment.
Among 486 unrelated people who had undergone geno-
typing for the CYP3A5 *3 allele to establish baseline data for a
DNA bank for the study of pharmacogenetics in Koreans
(data not published), 16 people with expressor alleles (*1*1
or *1*3 alleles) and 16 with non-expressor alleles (*3*3 alle-
les) volunteered to participate in our study. The 2 groups did
not differ significantly in terms of age, height or weight. The
participants were ascertained to be healthy by medical his-
tory, physical examination, vital signs and routine clinical
laboratory tests performed within 3 weeks before the start of
the study. None was a regular heavy drinker or a smoker, or
had a body weight more than 120% of his or her ideal weight.
Patients were given a loading oral dose of 300 mg of
clopidogrel (Plavix; Sanofi-Synthelabo Korea) followed by
daily oral doses of 75 mg for 6 days. A platelet aggregation
test was performed at baseline and at 4 hours, 24 hours and
6 days after the loading dose. After a washout period of 28
days, we performed the same experiment but with a pre-
treatment of 200 mg of itraconazole (Sporanox cap;
Janssen Korea) for 4 days to assess the effect of CYP3A5
genotype on the antiplatelet efficacy of clopidogrel. Itra-
conazole is a well-known CYP3A inhibitor and has been
frequently used in pharmacokinetic and pharmacodynamic
experiments of CYP3A4 substrates.20–22 Therefore, we chose
itraconazole for CYP3A4 inhibition. (The 2 dosing regi-
mens for phase 1 of the study are appear in Appendix 1,
available online at www.cmaj.ca/cgi/content/full
/174/12/1715/DC1.) Participants were instructed to refrain
from taking other medications, herbal drugs, alcohol, caf-
feinated beverages and grapefruit products for the 7 days
before and the 7 days during the clopidogrel-only regimen
and the 10 days before and the 7 days during the clopido-
grel plus itraconazole regimen.
Platelet aggregation was measured using platelet-rich
plasma stimulated with 5 µmol/L ADP and was assessed with
a Chronolog Lumi-Aggregometer (model 560-Ca; Chronolog
Corporation) equipped with an AggroLink software pack-
age.23 After inverting the vacutainer tube 3–5 times, the
blood-citrate mixture was centrifuged at 1200 g for 2.5 min-
utes. The platelet count was determined in the platelet-rich
plasma and adjusted to 3.0 × 105/mL with homologous
platelet-poor plasma. Aggregation was expressed as the max-
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Fig. 1: A: Adenine diphosphate (ADP) is an important physiologic agonist that plays a vital role in normal hemostasis and thrombosis.
The P2Y12 receptor of platelets signals through a Galpha i coupled G-protein receptor (Gi2 coupled) and is important for potentiation of
platelet activation mediated by other physiologic agonists, including collagen, von Willebrand factor and thromboxane A2.
18 B: Inhibi-
tion of ADP-induced platelet aggregation by clopidogrel. Clopidogrel is a prodrug requiring metabolism by cytochrome P450 (CYP) 3A
isoforms in order to be active. The active metabolite of clopidogrel blocks the platelet’s P2Y12 receptor.





















imal percentage change in light transmittance from the base-
line value, using platelet-poor plasma as a reference. The
change in platelet aggregation after clopidogrel treatment
was expressed as the absolute reduction in aggregation
achieved by 5 µmol/L of ADP after clopidogrel administration
compared with the baseline aggregation values before clopi-
dogrel administration.6
Phase II
The study protocol was approved by the SNUH Institutional
Review Board, and the study was conducted at the SNUH car-
diovascular centre. All subjects provided written informed
consent before enrolment.
We enrolled consecutive patients at the Seoul National
University Cardiovascular Center who had undergone suc-
cessful coronary angioplasty with implantation of bare-metal
stents after pretreatment with clopidogrel for at least 24
hours from November 2001 to August 2003. We excluded pa-
tients who underwent primary percutaneous coronary inter-
vention, received drug-eluting stents, were treated with ticlo-
pidine or were in cardiogenic shock. DNA analysis was
performed in all cases to determine the patients’ CYP3A5
genotypes. All patients gave informed consent to participate
in the study.
Coronary angioplasty and stent implantation were per-
formed using conventional techniques.24 Antiplatelet therapy
consisted of ASA (100–300 mg/d, prescribed indefinitely) and
clopidogrel (75 mg/d after a 300-mg loading dose), adminis-
tered for at least 4 weeks after the procedure. Other anti-angi-
nal and antihypertensive medications were given at the treat-
ing physician’s discretion. All treating physicians were blind
to the results of the DNA analysis.
Genomic DNA was prepared from the whole blood of each
subject by means of standard methods.25 The presence of the
CYP3A5*3 allele was determined by mismatch polymerase
chain reaction (PCR)-restriction fragment length polymor-
phism analysis, as previously reported.20 In brief, genomic
DNA was amplified using CYP3A5 6956Fm (5′-CTT TAA
AGA GCT CTT TTG TCT CTC A-3′) as the forward primer
and CYP3A5 7155R (5′-CCA GGA AGC CAG ACT TTG AT-3′)
as the reverse primer. After amplification, the 200-base pair
(bp) PCR product was digested using the enzyme DdeI. Di-
gestion of the CYP3A5*3 allele yielded fragments of 22, 71
and 107 bp, and digestion of the CYP3A5*1 allele yielded frag-
ments of 71 and 129 bp.
The end point of phase 2 was a composite of
atherothrombotic events (cardiac death, myocardial infarc-
tion and nonhemorrhagic cerebral infarction) within 1 and 6
months after stent implantation. The cause of all deaths was
regarded as cardiovascular unless there was documented evi-
dence of a clear noncardiovascular cause. Myocardial infarc-
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Fig. 2: A: Cytochrome P450 (CYP) 3A4 and CYP3A5 are major isoforms of the CYP3A system. Total CYP3A activity accounts for 20% of all
phase I reactions in the liver and metabolizes more than 50% of drugs. Under usual conditions, where both CYP3A4 and CYP3A5 con-
tribute to total CYP3A activity, CYP3A4 is probably the main contributor. Therefore, the antiplatelet activity of clopidogrel may not differ
substantially between patients with the CYP3A5 expressor genotype and those with the non-expressor genotype. B: In the presence of
multiple substrates or inhibitors, CYP3A4 is more easily inhibited than CYP3A5, and therefore CYP3A5 becomes the main contributor to




















tion was defined as the presence of at least 2 of the following
findings: ischemic symptoms; cardiac enzyme (CK MB) con-
centration at least twice the upper limit of normal; or new
electrocardiographic changes compatible with myocardial
infarction. Nonhemorrhagic cerebral infarction was defined
as a new focal neurologic deficit of vascular origin lasting at
least 24 hours that was proven to be nonhemorrhagic by ei-
ther CT or MRI scanning. The follow-up protocol included a
medical visit at the outpatient clinic at 1 month after stent
placement and every 2 or 3 months thereafter. Clinical events
were assessed on the basis of the information provided by
hospital readmission records, the referring physician or a
phone interview with the patient. The investigators who eval-
uated the clinical end points were blinded to the results of
the DNA analysis.
Statistical analysis
Continuous variables are presented as means and standard
deviations (SDs). In phase 1, a repeated-measures analysis of
variance was used to compare platelet aggregation test re-
sults at baseline, 4 hours, 24 hours and 6 days after clopido-
grel administration, and the Student’s t test was used to
compare the degree of platelet inhibition between the 2
genotype groups.
In phase 2, the χ2 test was used to compare the incidence
of clinical end points between the genotype groups. A logis-
tic regression analysis, which included age, sex, diabetes
mellitus, hypertension, hypercholesterolemia, previous my-
ocardial infarction, clinical diagnosis, CYP3A5 genotype, left
ventricular ejection fraction, stent size, multivessel disease,
multivessel intervention and the number of co-administered
CYP3A substrates or inhibitors (lipophilic statins, metopro-
lol, diltiazem, nifedipine, cimetidine and losartan) as co-
variates, was performed to identify determinants of athero-
thrombotic events (cardiovascular death, myocardial
infarction and nonhemorrhagic stroke) after coronary artery
stenting within 6 months. A p value below 0.05 was consid-
ered statistically significant.
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Fig. 4: Change in platelet aggregation from baseline after ad-
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Fig. 3: Platelet aggregation in healthy volunteers taking clopidogrel, by CYP3A5 genotype (non-expressor v. expressor).
Results
Phase 1
The inhibition of platelet aggregation after clopidogrel treat-
ment was significant at all points compared with baseline in
both of the genotype groups (Fig. 3). When we compared the
efficacy of clopidogrel in terms of the change in aggregation
from baseline, there were no significant differences between
the 2 groups, although we observed a slight tendency for
those with the CYP3A5 expressor genotype to achieve greater
inhibition of platelet aggregation (Fig. 4).
After the washout period and treatment with the CYP3A4
inhibitor itraconazole, clopidogrel significantly inhibited
platelet aggregation at all time points only among the subjects
with the CYP3A5 expressor genotype (Fig. 5). In contrast,
clopidogrel had a significant effect only on day 7 among those
with the non-expressor genotype (Fig. 5, right panel). In terms
of the change in aggregation from baseline, the change was
significantly greater among those with the expressor genotype
than among those with the non-expressor genotype at
4 hours, 24 hours and 6 days after baseline (Fig. 6).
Phase 2
A total of 348 patients were enrolled in phase 2. In these pa-
tients, 453 lesions were treated with angioplasty and implan-
tation of bare-metal stents. Genotype analysis revealed the
following frequency among the patients: 33 (9%) had the
CYP3A5 *1*1 allele, 122 (35%) had the *1*3 allele, and 193
(55%) had the *3*3 allele; which gave a frequency of non-
expressor (*3) allele of 73%. These findings were consistent
with the Hardy–Weinberg expectations. The patients were di-
vided into 2 groups: those with the CYP3A5 expressor alleles
(n = 155) and those with the non-expressor allele (n = 193).
The clinical and angiographic characteristics of the patients
did not differ significantly between the 2 groups (Table 1),
nor was there a significant difference in the duration of clopi-
dogrel treatment (4.1 [SD 2.3] and 3.9 [SD 2.3] months in the
non-expressor and expressor groups respectively) or co-
administered drugs (Table 2).
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Fig. 6: Change in platelet aggregation from baseline after ad-
ministration of clopidogrel and pretreatment with itraconazole.
Six-month clinical follow-up data were available for all
patients (Table 3). During this period, atherothrombotic
events occurred in 17 patients (14 in the non-expressor
group and 3 in the expressor group). One myocardial in-
farction in the non-expressor group was due to subacute
stent thrombosis; all cases of stroke were confirmed as
nonhemorrhagic by means of imaging studies. All of the
patients in the non-expressor group who experienced an
atherothombotic event were taking both clopidogrel and
ASA at the time.
Multivariable analysis revealed the following as independ-
ent predictors of atherothrombotic events within 6 months
after coronary angioplasty and bare-metal stent implantation:
CYP3A5 non-expressor genotype, every increase in the num-
ber of co-administered CYP3A substrates or inhibitors, and a
cholesterol level of 5.18 mmol/L (200 mg/dL) or higher
(Table 4).
In the subgroup analysis according to genotype, the num-
ber of CYP3A metabolizers was an independent predictor of
atherothrombotic events only in patients with the CYP3A5
non-expressor genotype but not in those with the expressor
genotype (Table 5).
Interpretation
The results of our study demonstrate that the drug interac-
tion between clopidogrel and the CYP3A inhibitor itracona-
zole differed according to CYP3A5 genotype and that the
genotype may lead to different clinical outcomes after coro-
nary angioplasty with bare-metal stent implantation in clopi-
dogrel users.
CYP3A activity accounts for 20% of all phase I reactions in
the liver and metabolizes more than 50% of drugs.12 Since
CYP3A can easily be induced or inhibited by several drugs, the
variability of CYP3A activity may be a common cause of
drug–drug interactions.26 In the setting of CYP3A4 inhibition,
the activity of CYP3A5 may be the key determinant of CYP3A
activity.20 Under usual conditions, where both CYP3A4 and
CYP3A5 contribute to CYP3A activity, the antiplatelet activity
of clopidogrel did not differ significantly between the 2 geno-
type groups in phase 1 of our study. However, when CYP3A4
activity was inhibited preferentially by pretreatment with itra-
conazole, the antiplatelet activity of clopidogrel was signifi-
cantly greater among those with the CYP3A5 expressor geno-
type than among those with the non-expressor genotype. 
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Table 1: Baseline characteristics of patients undergoing 
coronary angioplasty and bare-metal stent implantation, by 
CYP3A5 genotype 
 
CYP3A5 genotype;  
no. (%) of patients*  
Characteristic 
Non-expressor 
n = 193 
Expressor
n = 155 p value 
Age, yr, mean (SD) 60.8 (11.0) 62.6 (8.7) 0.10 
Sex, female   55 (29) 47 (30) 0.73 
Diabetes mellitus   68 (35) 62 (40) 0.51 
Hypertension 115 (60) 86 (56) 0.45 
Hypercholesterolemia   57 (30) 48 (31) 0.74 
LVEF < 45%   26 (14) 19 (12) 0.87 
Previous MI   45 (23) 28 (18) 0.29 
Previous PCI   30 (16) 18 (12) 0.28 
Previous CABG     9   (5)   6   (4) 0.80  
Unstable angina or 
non-STEMI   96 (50) 80 (52) 0.75 
Multivessel disease   95 (49) 79 (51) 0.78  
Stents per lesion, 
mean no. (SD) 1.3 (0.6) 1.3 (0.6) 0.94  
Stent diameter, mm, 
mean (SD) 3.3 (0.5) 3.2 (0.6) 0.17  
Stent length, mm, 
mean (SD)  22.0 (7.4) 21.2 (6.6) 0.29  
Use of GP IIb/IIIa 
inhibitors     4   (2)   2   (1) 0.70  
Note: SD = standard deviation, LVEF = left ventricular ejection fraction, 
MI = myocardial infarction, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass graft surgery, STEMI = ST-segment elevation MI, 
GP = glycoprotein. 
*Unless stated otherwise.  
Table 2: Concurrent medication use among patients undergoing 
coronary angioplasty and bare-metal stent implantation  
 
CYP3A5 genotype;  
no. (%) of patients*  
Medication 
Non-expressor 
n = 193 
Expressor 
n = 155 p value 
Statin   92 (47.4)   64 (41.3) 0.33 
Atorvastatin   17   (8.8)   19 (12.3)  
Simvastatin   64 (33.2)   36 (23.2)  
Lovastatin      9   (4.6)     9   (5.8)  
Pravastatin      2   (1.0)      0  
β-Blocker 123 (63.4) 111 (71.6) 0.11 
Metoprolol   32 (16.5)   29 (18.7)  
Other    91 (46.9)   82 (52.9)  
Calcium-channel 
blocker   40 (20.6)   40 (25.8) 0.33 
Diltiazem    26 (13.4)   20 (12.9)  
Nifedipine      3   (1.9)     2   (1.0)  
Other    14   (7.6)   17 (11.0)  
Nitrate  111 (57.2)   93 (60.0) 0.66 
ACE inhibitor    79 (40.7)   50 (32.3) 0.11 
Angiotensin II receptor 
blocker   18   (9.3)   17 (11.0) 0.72 
Co-administered 
CYP3A metabolizer,† 
mean no. (SD)  0.97 (0.74) 0.87 (0.74) 0.22 
Note: ACE = angiotensin-converting enzyme, SD = standard deviation. 
*Unless stated otherwise. 
†Includes lipophilic statins, metoprolol, diltiazem, nifedipine, cimetidine and 
losartan. 
Azoles are inhibitors of the CYP3A system and are re-
ported to inhibit CYP3A4 more potently than CYP3A5, in
vitro15 and in vivo.20 When CYP3A is inhibited by multiple
substrates or inhibitors, CYP3A4 is more easily inhibited than
CYP3A5, and in this condition, CYP3A5 may be the main con-
tributor to total CYP3A activity.20 These previous reports
along with our results suggest that people with the CYP3A5
non-expressor genotype rely more on CYP3A4 activity, which
is more susceptible to drug interactions.
We also examined the clinical significance of the CYP3A5
genotype in determining the risk of atherothrombotic events
among patients using clopidogrel after coronary angioplasty
and bare-metal stent implantation. The clinical events in our
study (cardiac death, myocardial infarction and nonhemor-
rhagic stroke) were the same as those used in previous stud-
ies to represent atherothrombotic events.27 In our study,
atherothrombotic events occurred more frequently among
patients with the CYP3A5 non-expressor genotype. Vulnera-
bility to drug interaction of clopidogrel and the resulting
insufficient conversion to the active metabolite in these pa-
tients may have contributed to their worse clinical outcomes,
which is supported by the findings that the number of co-
administered CYP3A metabolizers was an independent risk
factor for atherothrombotic events only among patients with
the non-expressor genotype.
Our study has some limitations. First, in phase 1, we did
not assay the active metabolite of clopidogrel directly but,
rather, performed a platelet aggregation test with ADP as an
indirect marker of the active clopidogrel metabolite, as done
by previous investigators. Therefore, we cannot rule out the
involvement of other factors between the interaction of the
active metabolite and the platelet ADP receptor.28 Second, we
did not co-assay other CYP3A5 alleles or CYP3A4 polymor-
phism. Because other alleles in the CYP3A5 gene are rare (*2,
*6 and *7),29–32 we speculated that the CYP3A5*3 allele is re-
sponsible for most, if not all, of the polymorphic expression
of CYP3A5. Another limitation was the small number of pa-
tients enrolled in phase 2 of the study.
In summary, the degree of drug interaction between clopi-
dogrel and the CYP3A inhibitor itraconazole differed according
to CYP3A5 genotype. People with the CYP3A5 non-expressor
genotype were more vulnerable than those with the expressor
genotype to drug interaction between clopidogrel and the
CYP3A metabolizer, and patients taking clopidogrel may be at
increased risk of atherothrombotic events after coronary angio-
plasty with bare-metal stent implantation. Further studies in a
large population are warranted to confirm these findings.
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Table 3: Clinical outcomes after coronary angioplasty and bare-
metal stent implantation, by CYP3A5 genotype 
 
CYP3A5 genotype;  




n = 193 
Expressor
n = 155 p value 
At 1 mo    
Sudden death   1 0  
MI (subacute thrombosis)        6 (1) 3  
Nonhemorrhagic stroke   3 0  
Total 10 3 0.16  
1–6 mo    
Sudden death   0 0 — 
MI   4 0  
Nonhemorrhagic stroke   0 0  
Total   4 0 0.10 
6-mo cumulative 14 3 0.023 
Note: MI = myocardial infarction. 
Table 4: Risk factors for atherothrombotic events after coronary angioplasty and bare-metal stent 
implantation among patients taking clopidogrel 
Risk factor Unadjusted OR (95% CI) Adjusted OR (95% CI)* 
CYP3A5 non-expression (v. expression) 3.96 (1.12–14.0) 4.89 (1.28–18.7) 
Co-administered CYP3A metabolizers† (every  
increase in no.) 2.15 (1.15–4.03) 2.22 (1.10–4.47) 
Total cholesterol level ≥ 5.18 mmol/L  
(v. < 5.18 mmol/L) 1.01 (0.99–1.02) 1.02 (1.01–1.03) 
Age ≥ 65 yr (v. < 65 yr)  0.98 (0.94–1.03) 0.98 (0.93–1.03) 
Male sex (v. female)  1.74 (0.64–4.70) 2.08 (0.65–6.61) 
Previous MI (v. no previous MI) 0.80 (0.22–2.86) 0.72 (0.17–3.10) 
Diabetes mellitus (v. no diabetes) 1.52 (0.57–4.05) 1.15 (0.39–3.40) 
LV systolic ejection fraction < 45% (v. > 45%) 1.12 (0.25–5.07) 1.13 (0.20–6.34) 
Stent diameter ≥ 2.75 mm (v. < 2.75 mm) 0.89 (0.36–2.23) 0.66 (0.24–1.85) 
Stent length ≥ 20 mm (v. < 20 mm) 0.99 (0.92–1.06) 0.98 (0.91–1.06) 
Note: OR = odds ratio, CI = confidence interval, LV = left ventricle, MI = myocardial infarction. 
*Adjusted for CYP3A5 genotype, number of co-administered CYP3A metabolizers, cholesterol level, age, sex, previous MI, diabetes 
mellitus, LV systolic dysfunction (ejection fraction < 45%), stent diameter and stent length. 
†Includes lipophilic statins, metoprolol, diltiazem, nifedipine, cimetidine and losartan. 
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Table 5: Risk factors for atherothrombotic events after coronary angioplasty and bare-metal stent 
implantation in patients taking clopidogrel, by CYP3A5 genotype 
 
CYP3A5 genotype;  
adjusted OR (95% CI) 
Risk factor Non-expressor  Expressor  
Co-administered CYP3A metabolizers (every increase in no.)  3.07 (1.36–6.93) 0.29 (0.03–2.96) 
Total cholesterol level ≥ 5.18 mmol/L (v. < 5.18 mmol/L) 1.00 (0.99–1.02) 1.02 (0.98–1.05) 
Age ≥ 65 yr (v. < 65 yr) 0.97 (0.91–1.02) 1.10 (0.92–1.33) 
Stent length ≥ 20 mm (v. < 20 mm) 0.98 (0.90–1.07) 1.02 (0.82–1.26) 
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